Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation
EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year
Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.